Thank Galafold you on call. by everyone start to the with more morning quarter. performance Bradley good and will details on I providing the our you for
and breakdown for X, can quarter first see primarily revenue or Slide $XX.X reported strong consisted geographic quarter of you both from revenue during million, within two-thirds million or $XX by the in As split coming of U.S. business. line on we That’s expect of the reached one-third outside generated the we the continue The revenue million U.S. the Galafold grow parts XXXX of that $XX demand. remaining to as patient driven the of the with
our we to countries growth patient markets. across leading were pleased mentioned, continued in see Bradley As
at the Now the for last turning a XX% growth From currencies was over period period; the XX% exchange results XXXX foreign impact markets, same to in globally our all result, in be period as rates. to year versus strong perspective, global with same the X% for was the year-over-year Slide from a reported first delivering continues in the of first X, constant efforts. added Galafold negative revenue the The patients quarter. highlight quarter growth demand operational for our strength rate Galafold commercial of an major
Galafold globally, for growing net globally. new the truest growth look is trends growing the be measure of patients see demand to underlying report on teens to QX for and in fastest continues the the patients year the so of if which same increase, are of business, at indications Galafold. you on I’m Galafold period all high our that a disease treatment patient rate monthly to the this at in we continue last Galafold versus Fabry pleased continued and year, end the net growth
switch untreated plenty and over to countries approved as more of newly longest, amenable high continue we patients so segments. where achieving When in than quarter, diagnosed we’re and patients, of penetrate the starting populations, and market stronger grow the naïve see Galafold still XX% to we to been first the share there’s we uptake market global opportunity ended in market continue the mix we’ve of diagnosed while share treated are into had global to the within to we
that on Galafold go that impressive by and of underpinned XX%, who compliance stay Galafold. is exceed to reiterating patients rates on continue adherence All permanently that those belief our
U.S. the Galafold negotiating of continues by the a as of reimbursement Importantly, record got we’ve value to payors track very be of outside renegotiating and recognized successfully strong
markets, major to for we our on well trends in remains to first commitment it. uptake Based smaller are relentless growth ensuring quarter all Galafold across well continue markets. Galafold seen those the track of here with most performance as who anyone very we’ve on access XXXX, Our our the and seeing of continues needs as
strong, the historical We In ordering quarter of slide, patterns we and a expect of provided a Turning due of as given uneven that trends mentioned each side would a to typically past and you year. fluctuations. on that is during similar snapshot The year that variety remains Galafold Slide expect XXXX. have of right-hand occur rate the within that the X, the year. percent continue table five-year FX non-linear have to the sales will calls, on Galafold we including throughout this of growth growth factors, to occur
years. be diagnosed growth geographies, throughout made that know the key existing we of extensions. for the onto to five the and around co-drivers: global label there several by the revenue market into population, amenable We annual expanding sustained to anticipate Slide X, of in driven patients uptake demand in into penetrate to $X billion with moving new surpass Now further significant has into mutations markets, and is untreated potential XXXX Fabry segment Galafold continuing
are the efforts [indiscernible] reimbursement and just mentioned, of mechanisms and we world. compliance all rates As access positive around by adherence these supported and
we application Galafold including to markets Hong received and to of we’re in pricing we’ve a continue and by we on and screening, been diagnostic driven Canada, name entered initiatives diagnosing other negotiations support in and newborn approved submitted label. XX screening, now into extending share a on and to Zealand and has reimbursement pleased years marketing measures, patients well. in for risk To progress variety continuous authorization and recently into patients for few which Kong, in use also the the as above invest authorization New Galafold adolescent through we’ve high examples, new I’m that marketing recently expanding of our extension making
Europe. Also U.S. note orphan have in important here, exclusivity to the we and
matter our which XX of listed those provide In Orange coverage IP time patents, XXXXs until Galafold to of a now eight including us to late provides to Book addition the opportunity composition for long patents, and access the XX globally to us come. give
launch preparations from to XX, today less Pombiliti slide, a Now than successful of we happy that stand outline poised as moving and launch onto we’re On launch. Slide commercial quarter product are we Opfolda. another for the
Opfolda know, support that few recruited countries. markets. countries Amicus the launch over now the all a and major today, and That largely only the including in wave world has will to you with Pombiliti team and As trained has presence XX a around of Pompe They’re the stayed first same FTEs. additional fully launch Fabry
pleased note commercial patients support positioned been onto product group has I’m supply. to first of coming that to the
successful We a launch: payors, and for most have importantly in addition across experience experience reimbursement with chain, commercial, relationships all key access, areas the with regulatory, supply physicians. are and needed that drug
our and around the and living in Pompe world. experience relationships AT-GAA organization disease leverage to that with We’re world-class their we people confident deliver
mapping again countries promotional teams that with building our strong strategic the inventory a second medical and successfully, materials Market From our for around market at the planning we and educational partners products all are are is with publications, in we’ve been Our access initial successful launch together ability believe and a Amicus. now very also reimbursement the and we completed. disease rare at in launch doing and WuXi training with our education experience to in is ready, our Biologics, position world, complete.
call program me Jeff that, now and the pipeline highlight Chief AT-GAA our to updates. With Jeff? to Castelli, hand our let over Officer, Development
